Mediar Therapeutics: Global Licensing Agreement With Eli Lilly to Advance Mtx-463 Into a Phase 2 Clinical Trial for Idiopathic Pulmonary Fibrosis
Mediar Therapeutics: 全球货币许可协议与艾尔利莉合作,将Mtx-463推进至特发性肺纤维化的第2阶段临床试验
Mediar Therapeutics: Global Licensing Agreement With Eli Lilly to Advance Mtx-463 Into a Phase 2 Clinical Trial for Idiopathic Pulmonary Fibrosis
Mediar Therapeutics: 全球货币许可协议与艾尔利莉合作,将Mtx-463推进至特发性肺纤维化的第2阶段临床试验
使用浏览器的分享功能,分享给你的好友吧